What distinguishes Cangrelor (Kengreal) from other antiplatelet agents?

Cangrelor (Kengreal) is distinctive among antiplatelet agents primarily due to its classification as a P2Y12 inhibitor that is administered intravenously (IV). This route of administration allows for rapid onset of action, facilitating immediate platelet inhibition in acute settings, such as during percutaneous coronary interventions (PCI).

Most antiplatelet medications, like clopidogrel and prasugrel, are given orally and require some time for the body to absorb and start showing effects. Cangrelor, in contrast, bypasses the gastrointestinal tract and renal absorption, leading to a more immediate impact on platelet function, making it particularly useful in critical care scenarios where time is of the essence.

Regarding the other aspects, while Cangrelor is indeed a non-reversible inhibitor, this feature isn't unique to it among antiplatelet therapies, as other inhibitors share that property. Additionally, while there are some contraindications for Cangrelor, such as a history of bleeding disorders or if the patient is actively bleeding, presenting the idea that it has no contraindications would be misleading. Thus, the combination of being an intravenous P2Y12 inhibitor stands out as its primary distinguishing feature.